Abstract
Exudative age-related macular degeneration (AMD) is a major indication for the administration of intravitreal injections of anti-VEGF agents, which have been established as a very effective pharmacotherapy for this disease. However, treatment with anti-VEGF agents requires several patient visits for monitoring and treatment. Strategies for achieving a longer duration of pharmacological action are currently being developed. These include the development of longer-acting drugs, and of novel technologies to increase the duration of action of administered agents. This manuscript will review the novel drugs and technologies currently being developed for achieving a longer-action pharmacotherapy for exudative AMD.
| Original language | English |
|---|---|
| Pages (from-to) | 4860-4863 |
| Number of pages | 4 |
| Journal | Current Pharmaceutical Design |
| Volume | 24 |
| Issue number | 41 |
| DOIs | |
| State | Published - 2018 |
Keywords
- Age related macular degeneration
- Anti-vegf agents
- Intravitreal therapy
- Long acting
- Long term
- Pharmacotherapy